When: Deep pullback to $365-372 toward lower Bollinger / July uptrend line

Then: Deploy 30% of target weight

BUY with tighter parameters: smaller initial size (one-quarter not one-third), explicit invalidation rules, and full trim-and-wait policy around earnings intact

• Stock bounced 26 percent off July low but remains 9 percent below the 200 SMA, which the analyst characterizes as a counter-trend bounce rather than a coiled spring launch
• Current setup involves buying at upper end of recovery range before a binary earnings event in three weeks without confirmation from the 50 SMA
• Conservative proposes reducing Tier 1 from one-third to one-quarter, converting it from a conviction buy to a probe, with sizing up only if 50 SMA holds for at least 5 trading days
• Stop at 360 represents a 6 percent loss on full position (not the claimed 5 percent maximum), with stock falling 11 percent from Tier 1 fill and 200 SMA still 25 percent above
• Macro report characterizes record-high equity tape as fragile and sentiment-driven rather than fundamentals-driven, creating one-sided positioning risk
• Hospital capex budgets are rate-sensitive; 7.58 percent mortgage rates affect the marginal hospital ordering a $2 million da Vinci system, placing the placements annuity line under pressure
• The 5.2 billion cash balance is a multi-year margin of safety, not a near-term floor; stock went to 328 in July implying 117 billion market cap
• Forward P/E of 33 times with PEG of 1.89 shows the growth premium is already priced in; the 30 percent discount is from a likely overvalued January, not a discount to fair value (anchoring bias)
• Inventory up 21.7 percent year-over-year versus 18.5 percent revenue growth warrants watchlist attention as potential early sign of softer channel demand

→ vs aggressive: The 200 SMA is not an arbitrary line but the most-watched long-term trend filter in institutional community; until reclaimed on sustained basis, every rally is a counter-trend bounce by definition

→ vs aggressive: Tier 1 at current prices before any confirmation and the blended cost argument assumes all three tiers deploy; if only Tier 1 fills, position is fully exposed with no buffer from lower-cost tranches

→ vs aggressive: Rate environment risk is not zero; hospital capex is discretionary and rate-sensitive, affecting the placements annuity that drives long-term revenue, not just procedure volume

→ vs aggressive: The fortress balance sheet is a multi-year margin of safety, not a near-term floor; markets compress multiples regardless of cash when fearing growth deceleration

→ vs aggressive: The 30 percent discount framing is anchoring bias; the relevant comparison is forward earnings against history and peers, not against an overvalued January price

→ vs aggressive: Inventory growth of 21.7 percent year-over-year significantly outpacing revenue growth of 18.5 percent warrants attention and is being glossed over

BUY ISRG with conditional tiered entry, full trim discipline into earnings, and position size calibrated to tolerate 15-20% drawdown

• Supports directional BUY based on fundamental thesis: Da Vinci 5 cycle, international penetration, switching costs, recurring revenue, fortress balance sheet, expanding margins, accelerating top line
• Tier 1 should be one-quarter of target weight (not one-third as aggressive suggests), deployed either after daily close above 400 with volume confirmation OR on dip to 392 to 400 zone
• Tier 2 and Tier 3 stay as designed, with Tier 3 only deploying if 50 SMA at 382 holds on closing basis
• Earnings trim policy is most important risk control: trim 25 to 33 percent into Q3 print regardless of direction, redeploy only on confirmed beat-and-raise or post-earnings dip holding 50 SMA
• Stock is still 9.2 percent below its 200-day moving average with binary event in three weeks
• Inventory build of 21.7 percent against 18.5 percent revenue growth is a yellow flag requiring management attention on Q3 call
• Position must tolerate drawdown to 330 without forced sale (15 to 20 percent tolerance); no leverage
• Invalidation: close below 382 ends the staged entry
• ATR at 11.46, beta at 1.46
• Agrees hospital capex slowdown risk exists but characterizes it as 2027 story, not Q3 2026 story

→ vs aggressive: Confirmation bias treating neutral sentiment as bullish; cash floor argument flawed since stock literally traded at 328 in July (117 billion market cap against 5.2 billion cash on 357 million diluted shares)

→ vs aggressive: Using fragile tape as proof of safety while the same research flags the tape as a risk source is cherry-picking

→ vs aggressive: Treating long-term thesis as tactical trigger; 30 percent discount cited is anchoring bias, not a timing signal

→ vs conservative: Reduction from one-third to one-quarter is cosmetic not meaningful in dollar exposure terms on moderately sized overweight position

→ vs conservative: 200 SMA reclaim is approximately 10 percent above current prices and waiting for it defeats the purpose of staged entry; technical report itself says risk/reward favors initiating on pullbacks to 392 to 400

→ vs conservative: Hospital capex sensitivity is technically true but practically slow-moving on multi-year decision cycles; placement slowdown is 2027 story, not current quarter story